BIOTRIAL BIOMETRICS

Their core work

Biotrial Biometrics is a French clinical measurement SME based in Rennes, specializing in quantitative biomarker assessment and biometric data collection for pharmaceutical and academic research trials. They operate as a specialist service provider — subcontracted into large EU research consortia to deliver objective, measurable endpoints for complex disease studies. Their work spans two disease domains: metabolic multimorbidity (diabetes, obesity, insulin resistance) and neuropsychiatric conditions (Alzheimer's, schizophrenia, depression), with a clear move toward digital biomarker development and transdiagnostic measurement frameworks. Given their parent brand Biotrial — one of France's largest independent CROs — this unit likely handles the quantitative and wearable-sensor side of clinical and preclinical studies.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (PRIME, 2020), the focus was on metabolic multimorbidity — insulin, diabetes, obesity — alongside neuropsychiatric comorbidities like dementia and Alzheimer's, with a strong intervention angle (exercise, diet, medication). By their second project (PRISM 2, 2021), the emphasis had clearly shifted toward psychiatric stratification and measurement methodology: transdiagnostic frameworks, translational neuroscience, digital biomarkers, and quantitative biology replaced the lifestyle and metabolic keywords. This signals a deliberate move away from broad metabolic endpoints toward more sophisticated, technology-driven psychiatric biomarker development.

Biotrial Biometrics appears to be repositioning toward digital and quantitative psychiatric biomarkers — a high-growth area where objective measurement tools for CNS trials are in short supply — making them a relevant partner for any consortium needing validated digital endpoints in neuropsychiatric research.

How they like to work

Biotrial Biometrics has participated exclusively as a third party in both H2020 projects, meaning they were subcontracted rather than holding a formal consortium seat — a pattern typical of specialized CRO-adjacent service providers who deliver defined measurement packages. Despite this limited formal role, they are connected to 33 distinct partners across 11 countries through just 2 projects, indicating they were embedded in large, well-networked European consortia. This suggests they are easy to bring into a project as a named service provider without the governance overhead of a full partner slot.

With 33 unique consortium partners across 11 countries from only 2 projects, Biotrial Biometrics has built a disproportionately wide European network for its size — both projects (PRIME and PRISM 2) were large RIA consortia, likely 10–20 partners each. Their reach is pan-European with no obvious single-country concentration.

What sets them apart

Biotrial Biometrics sits at the intersection of two usually separate worlds: metabolic disease quantification and neuropsychiatric biomarker development — a rare dual competence that fits the growing recognition that conditions like Alzheimer's and depression have metabolic components. As an SME affiliated with Biotrial (a major French CRO), they combine the agility and specialist focus of a small company with access to established clinical infrastructure. For consortium builders, they offer a credible, experienced third-party measurement provider that can be slotted into Health RIA projects without requiring a leadership role or large budget allocation.

Highlights from their portfolio

• PRISM 2
  Tackles one of the hardest problems in CNS drug development — finding shared biological markers across Alzheimer's, schizophrenia, and depression — using a transdiagnostic approach that could reshape how psychiatric trials are designed.
• PRIME
  Addresses the clinical reality that metabolic and neuropsychiatric conditions co-occur (the 'multimorbidity' challenge), spanning diabetes, obesity, dementia, and autism within a single prevention-and-remediation framework.